Teva’s Frost Outlines Opko Strategy Amidst Activist Shareholder Assault
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma is trying to refocus investor interest on its strategy, away from recent Wall Street criticisms of the company and its chairman and CEO, Phillip Frost.